Approaches to vaccination against the new coronavirus infection in solid organ recipients
https://doi.org/10.18093/08690189-2022-32-2-239-243
Abstract
Solid organ recipients represent a high risk group for all adverse outcomes associated with SARS-CoV-2 infection due to the immunosuppressive treatment and the presence of comorbidities such as cardiovascular disease, diabetes mellitus, and arterial hypertension.
The aim of the study was to assess the ability of solid organ recipients to form immune response after vaccination against a new coronavirus infection and safety of the vaccines in this population.
Conclusion. An analysis of the literature and the results obtained in Russia show that vaccines against SARS-CoV-2 do not cause unusual clinical events in recipients of solid organs. Levels of post-vaccination antibodies in these patients, especially in the elderly patients shortly after transplantation who take antimetabolites, are lower than in the general population. This group of patients needs alternative immunization schemes against the new coronavirus infection, which may include more than two booster doses or a combination of different types of vaccines, as well as doubling the vaccine dose.
About the Authors
V. B. Polishchuk
I.I.Mechnikov Research Institute of Vaccines and Sera
Russian Federation
Russian Federation
Valentina B. Polishchuk, Candidate of Medicine, Senior Researcher, Laboratory оf Vaccination аnd Immunotherapy of Allergic Diseases
Malуy Kazennуy per. 5a, Moscow, 105064, Russia
M. P. Kostinov
I.I.Mechnikov Research Institute of Vaccines and Sera;
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Mikhail P. Kostinov, Doctor of Medicine, Professor, Head of the Laboratory for Vaccine Prevention and Immunotherapy of Allergic Diseases, I.I.Mechnikov Research Institute of Vaccines and Sera; Head of the Department of Epidemiology and Modern Vaccination Technologies, I.M.Sechenov First Moscow State Medical University
Malуy Kazennуy per. 5a, Moscow, 105064, Russia;
ul. Trubetskaya 8, build. 2, Moscow, 119991, Russia
A. A. Ryzhov
I.I.Mechnikov Research Institute of Vaccines and Sera
Russian Federation
Russian Federation
Aleksey A. Ryzhov, Senior Researcher, Laboratory оf Vaccination аnd Immunotherapy of Allergic Diseases
Malуy Kazennуy per. 5a, Moscow, 105064, Russia
N. A. Karchevskaya
N.V.Sklifosovskiy State Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
Russian Federation
Natal’ya A. Karchevskaya, Researcher, Department of Urgent Thoracoabdominal Surgery
Bolshaya Sukharevskaya pl. 3, Moscow, 129090, Russia
E. A. Тarabrin
N.V.Sklifosovskiy State Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
Russian Federation
Evgeniy A. Tarabrin, Doctor of Medicine, Head of the Scientifi Department of Urgent Thoracoabdominal Surgery
Bolshaya Sukharevskaya pl. 3, Moscow, 129090, Russia
T. E. Kallagov
N.V.Sklifosovskiy State Research Institute of Emergency Care, Moscow Healthcare Department
Russian Federation
Russian Federation
Taymuraz E. Kallagov, Researcher, Department of Urgent Thoracoabdominal Surgery
SPIN: 6358-5525;
Author ID: 960789
Bolshaya Sukharevskaya pl. 3, Moscow, 129090, Russia
References
1. Ao G., Wang Y., Qi X. et al. The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant. Rev. (Orlando). 2021; 35 (3): 100628. DOI: 10.1016/j.trre.2021.100628.
2. Belsky J.A., Tullius B.P., Lamb M.G. et al. COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. J. Infect. 2021; 82 (3): 329–338. DOI: 10.1016/j.jinf.2021.01.022.
3. CDC. COVID-19. People with certain medical conditions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
4. ECDC. COVID-19 vaccination and prioritization strategies in the EU/EEA. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf
5. CDC. Summary document for interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf
6. ISHLT. Guidance from the International Society for Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. Revised: February 1, 2021. Available at: https://ishlt.org/ishlt/media/documents/SARS-CoV-2_Guidance-for-Cardiothoracic-Transplant-and-VAD-center.pdf
7. Polack F.P., Thomas S.J., Kitchin N. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020; 383 (27): 2603–2615. DOI: 10.1056/NEJMoa2034577.
8. Sahin U., Muik A., Vogler I. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specifi T cells in humans. Nature. 2021; 595 (7868): 572–577. DOI: 10.1038/s41586-021-03653-6.
9. Shostak Y., Shafran N., Heching M. et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir. Med. 2021; 9 (6): e52–53. DOI: 10.1016/S2213-2600(21)00184-3.
10. Itzhaki Ben Zadok O., Shaul A.A., Ben-Avraham B. et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients a prospective cohort study. Eur. J. Heart Fail. 2021; 23 (9): 1555–1559. DOI: 10.1002/ejhf.2199.
11. Boyarsky B.J., Werbel W.A., Avery R.K. et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021; 325 (17): 1784–1786. DOI: 10.1001/jama.2021.4385.
12. Boyarsky B.J., Werbel W.A., Avery R.K. et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021; 325 (21): 2204–2206. DOI: 10.1001/jama.2021.7489.
13. Korth J., Jahn M., Dorsch O. et al. Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (pfizer-bioNTech). Viruses. 2021; 13 (5): 756. DOI: 10.3390/v13050756.
14. Grupper A., Rabinowich L., Schwartz D. et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am. J. Transplant. 2021; 21 (8): 2719–2726. DOI: 10.1111/ajt.16615.
15. Mazzola A., Todesco E., Drouin S. et al. Poor antibody response after two doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine in transplant recipients. Clin. Infect. Dis. 2022; 74 (6): 1093–1096. DOI: 10.1093/cid/ciab580.
16. Havlin J., Svorcova M., Dvorackova E. et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J. Heart Lung Transplant. 2021; 40 (8): 754–758. DOI: 10.1016/j.healun.2021.05.004.
17. Rabinowich L., Grupper A., Baruch R. et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J. Hepa tol. 2021; 75 (2): 435–438. DOI: 10.1016/j.jhep.2021.04.020.
18. Rozen-Zvi B., Yahav D., Agur T. et al. Antibody response to SARSCoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin. Microbiol. Infect. 2021; 27 (8): 1173.e1–1173. e4. DOI: 10.1016/j.cmi.2021.04.028.
19. Narasimhan M., Mahimainathan L., Clark A.E. et al. Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines. Vaccines (Basel). 2021; 9 (7): 708. DOI: 10.3390/vaccines9070708.
20. Bertrand D., Hamzaoui M., Lemée V. et al. Antibody and T-cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J. Am. Soc. Nephrol. 2021; 32 (9): 2147–2152. DOI: 10.1681/ASN.2021040480.
21. Peled Y., Ram E., Lavee J. et al. BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response. J. Heart Lung Transplant. 2021; 40 (8): 759–762. DOI: 10.1016/j.healun.2021.04.003.
22. Cucchiari D., Egri N., Bodro M. et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am. J. Transplant. 2021; 21 (8): 2727–2739. DOI: 10.1111/ajt.16701.
23. Marinaki S., Adamopoulos S., Degiannis D. et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am. J. Transplant. 2021; 21 (8): 2913–2915. DOI: 10.1111/ajt.16607.
24. Schmidt T., Klemis V., Schub D. et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am. J. Transplant. 2021; 21 (12): 3990–4002. DOI: 10.1111/ajt.16818.
25. Kamar N., Abravanel F., Marion O. et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N. Engl. J. Med. 2021; 385 (7): 661–662. DOI: 10.1056/NEJMc2108861.
26. Del Bello A., Abravanel F., Marion O. et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am. J. Transplant. 2021; 22 (1): 322–323. DOI: 10.1111/ajt.16775.
27. Werbel W. A., Boyarsky B. J., Ou M. T. et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann. Intern. Med. 2021; 174 (9): 1330–1332. DOI: 10.7326/L21-0282.
28. DGS-Urgent. Vaccins contre La COVID-19: modalites d’administration des rappels. April 11, 2021. Available at: https://www.mesvaccins.net/textes/dgs_urgent_n43_vaccination_modalites_d_administration_des_rappels.pdf
29. FDA. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. August 12, 2021. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised
30. ASTS. ASTS position on COVID-19 vaccine and transplant patients. August 25, 2021. Available at: https://asts.org/news-and-publications/asts-news/2021/08/25/asts-position-on-covid-19-vaccine-transplant-patients#.Ym10_2hByUl
31. Schmidt T., Klemis V., Schub D. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat. Med. 2021; 27 (9): 1530–1535. DOI: 10.1038/s41591-021-01464-w.
32. Natori Y., Shiotsuka M., Slomovic J. et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin. Infect. Dis. 2018; 66 (11): 1698–1704. DOI: 10.1093/cid/cix1082.
33. Mombelli M., Rettby N., Perreau M. et al. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: a randomized controlled trial. Vaccine. 2018; 36 (41): 6163–6169. DOI: 10.1016/j.vaccine.2018.08.057.
Review
For citations:
Polishchuk V.B., Kostinov M.P., Ryzhov A.A., Karchevskaya N.A., Тarabrin E.A., Kallagov T.E. Approaches to vaccination against the new coronavirus infection in solid organ recipients. PULMONOLOGIYA. 2022;32(2):239-243. (In Russ.) https://doi.org/10.18093/08690189-2022-32-2-239-243
Views:
389
Email this article 